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Abstract. Urinary neutrophil gelatinase‑associated lipocalin 
(uNGAL) is produced in response to tubular epithelial injury 
and is a biomarker of tubulointerstitial injury. The aim of the 
present study was to examine whether acute kidney injury 
(AKI) could be predicted by measuring uNGAL in very 
low‑birth weight (VLBW) infants. Forty VLBW infants with 
birthweight below 1,500 g were enrolled in the present study. 
uNGAL and serum creatinine (sCre) were measured daily 
from postnatal days 0 to 8. Infants with sCre ≥1.2 mg/dl were 
diagnosed with AKI. The relationship of uNGAL with sCre 
was measured on the day after uNGAL measurement (next‑day 
sCre) was examined. The results showed that 16 infants had 
sCre ≥1.2 mg/dl in this period. Logistic regression analysis 
revealed that uNGAL on postnatal days 2, 3, 4, 5 and 6 was 
correlated with next‑day sCre (P<0.05). uNGAL corrected by 
urinary Cre (uCre) (uNGAL/uCre) was only correlated with an 
increase in next‑day sCre on postnatal days 5 and 6 (P<0.05). 
For the logistic analysis, subjects with high and low uNGAL 
levels based on the median value for each day, uNGAL on post‑
natal days 2, 3 and 6 in the high uNGAL group was correlated 
with an increase in next‑day sCre. Thus, AKI may be predicted 
by measuring uNGAL in VLBW infants. This measurement 
was non‑invasive, and is potentially useful for the evaluation of 
renal function in VLBW infants.
Introduction
Renal function is immature in premature infants, and this can 
easily result in the development of acute kidney injury (AKI) 
due to changes in blood pressure and respiratory conditions, 
as well as administration of some drugs. It has been found that 
8‑24% of premature infants admitted to a neonatal intensive 
care unit (NICU) develop AKI (1,2). Additionally, AKI may 
contribute to the mortality of very low‑birth weight (VLBW) 
infants with a birth weight of <1,500 g (3). Serum creatinine 
(sCre) is often used as a biomarker for renal function, albeit 
it is affected by parameters including muscle mass, gender, 
ethnicity, and medication (4). Additionally, several days 
are usually required before an increase in sCre level can be 
detected in infants with AKI (5).
Neutrophil gelatinase‑associated lipocalin (NGAL) is a 
25‑kDa protein from the lipocalin family that is primarily 
secreted by activated neutrophils (6). NGAL is produced in 
the granules of activated neutrophils and also by the nephron 
in response to any damage to tubular epithelium; therefore, 
NGAL can serve as a biomarker for tubulointerstitial injury (7). 
When the kidney is damaged, NGAL is mainly produced 
in the ascending thick limb of the loop of Henle and renal 
collecting tubule, and is immediately secreted into urine (8). 
Urinary NGAL (uNGAL) is increased with renal ischemia 
and associated acute tubular necrosis (9), and thus uNGAL 
is useful for the prediction of renal failure (10). uNGAL may 
also be an early marker of renal failure in adults and children 
after cardiac surgery or renal transplantation (11,12), and 
may be useful in the detection of chronic kidney failure in 
children (13), as well as the prediction of bronchopulmonary 
dysplasia in premature infants (14). The standard range of 
uNGAL in newborns, particularly VLBW infants, has been 
suggested to range between 2 and 150 ng/ml (15), albeit this 
has not been clearly established (16).
In the present study, we investigated whether an increase 
of uNGAL was useful for the early prediction of renal failure 
in VLBW infants.
Materials and methods
Subjects. The study subjects were infants who were born 
with a gestational age of 23 to <32 weeks and a birth 
weight of 500‑1,500 g, and were admitted to the NICU of 
Dokkyo Medical University Hospital from January, 2009 to 
December, 2010. Infants with chromosomal abnormalities, 
external deformities and those with life‑threatening diseases 
were excluded. Subsequently, a prospective single‑center study 
was performed.
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This study was performed after obtaining approval from 
the ethics committee of Dokkyo Medical University (approval 
no. 25042) and informed consent from the infants' parents.
Methods. uNGAL and sCre levels were measured daily from 
postnatal days 0 to 8. For the measurement of uNGAL, urine 
was collected using cotton balls or a urine sampling bag and 
the samples were stored at ‑80˚C. When urine was collected 
with a cotton ball, the ball was applied to the vulva in the diaper 
and was collected after it was immersed in urine. uNGAL and 
urinary Cre (uCre) levels were unaffected by the measurement 
method (17,18). Furthermore, measurements of uNGAL levels 
in 23 subjects using urine sampling bags and cotton balls 
produced values of 134.5±128 and 132.1±125 ng/ml, respec‑
tively, with no significant difference (P=0.95). Based on these 
data, we collected urine using one of these methods.
uNGAL was measured using an NGAL ELISA kit 036 
(BioPorto Diagnostics, Gentofte, Denmark) that specifi‑
cally detects human NGAL. The urine sample was diluted 
500 times using dilution solution provided in the NGAL kit. 
NGAL standards or diluted samples (100 µl) were applied to 
precoated microwells in duplicate, incubated for 1 h at 23±2˚C, 
and washed with washing buffer. Subsequently, biotinylated 
NGAL antibody and HRP‑streptavidin were added to wells and 
incubated for 1 h via centrifugation using a shaking platform 
(200 rpm; Taiyo Micromixer, Taiyo Science Industrial Co. Ltd., 
Tokyo, Japan). TMB substrate was added for 10 min in the dark 
prior to adding stop solution. The NGAL concentration was then 
measured at 450 nm wavelength in each well with a reference 
reading at 620 nm in blank wells. The average was considered to 
be the uNGAL value. uCre was measured in the same samples.
sCre is generally used as an index of renal dysfunction 
in the first postnatal month (16) and is obtained using blood 
samples obtained in daily medical routine tests. AKI is 
diagnosed based on sCre ≥1.2 mg/dl (17). Subjects with sCre 
levels of ≥1.2 and <1.2 mg/dl were compared using U tests for 
gestational age, birth weight, and Apgar score, and Chi‑square 
tests for gender. Indomethacin was employed for the treat‑
ment of patent ductus arteriosus in immature infants, and 
aminoglycoside antibiotics were used, as well as mechanical 
ventilation, antenatal steroid therapy, delivery method, and 
onset of chorioamnionitis for the diagnosis of AKI (17).
Statistical analysis. SPSS 11.0J for Windows (SPSS, Inc., 
Chicago, IL, USA) software was used for statistical analysis. 
Logistic regression analyses were performed for uNGAL and 
uNGAL/uCre with next‑day sCre. Subjects were divided into 
low and high uNGAL groups based on the median uNGAL level 
on each day. Logistic regression analysis was then performed 
to calculate the odds ratio for next‑day sCre as a predictor of 
high uNGAL, with the value for the low uNGAL group set to 1. 
Similar analyses were conducted for uNGAL/uCre. P<0.05 was 
considered to indicate a statistically significant difference.
Results
Subjects were stratified based on their weight into four 
groups: i) 500‑750 g group (n=9); ii) 751‑1,000 g group (n=15); 
iii) 1,001‑1,250 g group (n=8); and iv) 1,251‑1,500 g group 
(n=8). The gestational ages ranged from 23 weeks and 0 days 
to <26 weeks (n=13), 26 weeks and 0 days to <29 weeks 
(n=18), and 29 weeks and 0 days to <32 weeks (n=9). During 
the study period, 16 subjects had sCre ≥1.2 mg/dl. Groups 
with sCre ≥1.2 and <1.2 mg/dl had significant differences in 
gestational age, birthweight, and 1‑ and 5‑min Apgar scores, 
but no significant differences in gender, delivery method, use 
of antenatal steroids, chorioamnionitis, use of indomethacin, 
use of aminoglycoside antibiotics, or mechanical ventilation 
were detected (Table I).
uNGAL levels measured in all subjects on postnatal 
days 0 to 8 are shown in Fig. 1. The median uNGAL was 
higher than the reported standard value in VLBW infants. 
There were significant differences in uNGAL between post‑
natal days 1 and 2, and between postnatal days 2 and 3 (Fig. 1). 
Based on logistic regression analysis, an increase in next‑day 
sCre was significantly correlated with uNGAL on postnatal 
days 2, 3, 4, 5 and 6 (P<0.05), but with uNGAL/uCre only on 
postnatal days 5 and 6 (P<0.05).
Table I. Infant and maternal characteristics.
Characteristics sCre ≥1.2 mg/dl (n=16) sCre <1.2 mg/dl (n=24) P‑value
Gestational age (weeks)a 26.3±1.9  27.6±2.0 0.030
Birthweight (g)a   845±251 1,055±252 0.013
Normal spontaneous delivery (%)   7 (44) 14 (58) 0.520
1‑min Apgara   4.0±2.1   5.6±2.1 0.030
5‑min Apgara   6.9±1.1   7.8±1.7 0.029
Female (%)   9 (56) 10 (42) 0.520
Antenatal steroids (%)   9 (56) 18 (75) 0.305
Chorioamnionitis (%) 11 (69) 16 (67) 1.000
Indomethacin (%) 12 (75) 12 (50) 0.188
Aminoglycoside (%) 14 (88) 16 (67) 0.263
Mechanical ventilation (%) 11 (69)   8 (33) 0.051
aMean ± standard deviation. sCre, serum creatinine.
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Table II. Logistic analysis of uNGAL and next‑day serum creatinine.
 uNGAL (ng/ml)
 ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
Postnatal No. Low High Odds ratio P‑valuea
Day 0 23     5.9‑167.7 167.8‑499.0 ‑ 0.744
Day 1 40     6.6‑193.2 193.3‑542.1 3.00 (0.51‑17.74) 0.063
Day 2 40   15.8‑288.5 288.6‑541.4 7.36 (1.34‑40.55) 0.009
Day 3 40   14.3‑359.6 359.7‑572.6 15.52 (1.73‑139.26) 0.010
Day 4 40   18.6‑326.2 326.3‑551.8 ‑ 0.013
Day 5 40   17.0‑239.9 240.0‑542.2 ‑ 0.011
Day 6 40   15.6‑233.7 233.8‑541.0 10.23 (1.12‑93.34) 0.004
Day 7 40   15.0‑237.6 237.7‑542.0   6.33 (0.67‑60.16) 0.122
Day 8 17 158.6‑298.9 299.0‑462.3 ‑ 0.463
‑, indicates no data because there were no cases with increased serum creatinine in the low group, and thus logistic regression analysis was not 
possible. aUrinary neutrophil gelatinase‑associated lipocalin (uNGAL) was included as a continuous, rather than a categorical, variable in the 
logistic regression model.
Table III. Logistic analysis of uNGAL/uCre and next‑day sCre.
 uNGAL/uCre
 ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
Postnatal No. Low High Odds ratio P‑valuea
Day 0 23 1.0‑19.4 19.5‑95.7 ‑ 0.486
Day 1 40 0.8‑18.9 19.0‑82.4 1.42 (0.27‑7.34) 0.228
Day 2 40 1.6‑26.0 26.1‑61.8 2.15 (0.52‑9.00) 0.144
Day 3 40 0.9‑21.2 21.3‑73.1 3.05 (0.66‑14.13) 0.159
Day 4 40 1.6‑24.6 24.7‑53.6 ‑ 0.110
Day 5 40 1.7‑18.1 18.2‑52.6 8.14 (0.88‑75.48) 0.031
Day 6 40 1.7‑20.4 20.5‑64.9 3.86 (0.67‑22.11) 0.014
Day 7 40 1.3‑21.5 21.6‑78.0 2.53 (0.41‑15.75) 0.065
Day 8 17 9.5‑22.7 22.8‑65.1 ‑ 0.524
‑, indicates no data because there were no cases with increased sCre in the low group, and thus logistic regression analysis was not possible. 
auNGAL/uCre was included as a continuous, rather than a categorical, variable in the logistic regression model. uNGAL, urinary neutrophil 
gelatinase‑associated lipocalin; uCre, urinary creatinine; sCre, serum Cre.
Figure 1. Urinary neutrophil gelatinase‑associated lipocalin in infants on postnatal days 0 to 8. *P=0.02 for day 1 vs. day 2, and day 2 vs. day 3 by Mann‑Whitney 
U test. NS, not significant.
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Subjects were also divided into low and high uNGAL 
groups based on the median uNGAL measured each day. 
Calculation of the odds ratio showed that next‑day sCre was 
a predictor of high uNGAL on postnatal days 2, 3 and 6 
(Table II). No relationship with next‑day sCre was detected for 
uNGAL/uCre on any day (Table III).
Discussion
The results of the present study have shown that, subjects 
with lower gestational age, lower birth weight, and lower 
1‑ and 5‑min Apgar scores had increased levels of sCre. 
Similar results were reported in previous studies (19,20). 
These results were consistent with findings showing that 
AKI occurs in 47‑61% of cases of neonatal asphyxia with a 
5‑min Apgar score of <7 (20‑22). It has been suggested that, 
compared to sCre, acute renal dysfunction in pediatric patients 
may be diagnosed more quickly based on NGAL in urine or 
blood after cardiac surgery (11). It was also reported that renal 
failure may be predicted more precisely with uNGAL because 
compared to blood NGAL levels, there was a marked increase 
in uNGAL levels (11). Thus, uNGAL is a more effective 
marker for renal dysfunction in children (11).
Higher levels of uNGAL have been detected in VLBW 
infants with a lower birth weight and lower gestational 
age (17), as well as in those with onset of AKI (23,24). The 
results showed that, uNGAL levels in the current study were 
higher than the recently reported standard value in VLBW 
infants (15,25). This difference may be explained by the fact 
that there were many premature infants with a gestational age 
<27 weeks among our subjects.
Next‑day sCre, rather than sCre on the day of uNGAL 
measurement, was found to be a predictor for uNGAL. A 
difference in correlations of uNGAL with uNGAL/uCre and 
sCre were found (26), but our results support those of previous 
studies showing that correction of uNGAL with uCre was not 
necessary (15,17,27). An increase in uNGAL (a marker of 
proximal tubular epithelium disorder) may occur before an 
increase in sCre (a marker of glomerular disorder), because 
nephrogenic renal dysfunction may develop when prerenal 
failure is protracted (28). Additionally, Cre excreted due to 
tubular disorder may be reabsorbed due to insufficient tubular 
function, which can cause an increase in sCre in infants with 
LBW (29,30). uNGAL is excreted from renal proximal tubular 
cells as a response to AKI (31) and nephrogenic injury (32), 
and is increased in patients with late‑onset sepsis (33).
uNGAL is not correlated with sCre in VLBW infants (16), 
however, our results suggested that uNGAL was a useful 
biomarker for the early diagnosis of renal failure in prema‑
ture infants by predicting an increase in next‑day sCre. The 
increase in sCre levels was significant in the high uNGAL 
group, and thus this group was likely to be at risk for AKI.
Further studies using bigger samples are needed to estab‑
lish standard daily uNGAL levels for early postnatal days. 
Measurement of uNGAL has the advantage of being non‑inva‑
sive for VLBW infants, and use of uNGAL in clinical practice 
may allow the prediction of renal failure, control of water 
intake, control of dosage of antibiotics that may induce renal 
failure, such as aminoglycosides and vancomycin for MRSA, 
and the need for use of indomethacin.
The most significant shortcoming of the present study was 
that we were not able to completely collect the maternal sCre 
data samples. This was because the sCre level of neonates 0 to 
3 days after birth were influenced by the maternal sCre through 
the placenta, and data were not reflected adequately (34‑36). In 
retrospect, this aspect should have been taken into consider‑
ation. Furthermore, because we only evaluated the relationship 
between uNGAL and sCre, the correlation with AKI was poor. 
We cannot disregard the possibility that AKI was overvalued. 
However, our results indicate that there was a correlation 
between uNGAL and sCre in VLBW infants, because it had 
the potential to function as the basic data for additional studies 
in the future. More clinical and basic studies on NGAL have 
been reported recently (37‑43). In summary, more research on 
the biological mechanism of the NGAL is necessary.
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